Dashboard
1
Poor Management Efficiency with a low ROE of 15.77%
- The company has been able to generate a Return on Equity (avg) of 15.77% signifying low profitability per unit of shareholders funds
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of -5.44% and Operating profit at -209.70% over the last 5 years
4
Negative results in Dec 24
5
Risky -
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.46%
0%
-17.46%
6 Months
-3.94%
0%
-3.94%
1 Year
27.35%
0%
27.35%
2 Years
16.86%
0%
16.86%
3 Years
125.93%
0%
125.93%
4 Years
-12.23%
0%
-12.23%
5 Years
-54.81%
0%
-54.81%
Santhera Pharmaceuticals Holding AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.44%
EBIT Growth (5y)
-209.70%
EBIT to Interest (avg)
-1.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.41
Sales to Capital Employed (avg)
0.66
Tax Ratio
0.75%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.51%
ROE (avg)
15.77%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-57.51
EV to EBIT
-3.99
EV to EBITDA
-4.49
EV to Capital Employed
3.79
EV to Sales
4.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.06%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
7.50
-1.60
568.75%
Operating Profit (PBDIT) excl Other Income
-42.20
-53.40
20.97%
Interest
20.20
16.40
23.17%
Exceptional Items
-6.60
5.20
-226.92%
Consolidate Net Profit
-71.10
-55.50
-28.11%
Operating Profit Margin (Excl OI)
-6,137.70%
0.00%
-613.77%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 568.75% vs -110.67% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -28.11% vs 18.02% in Dec 2021
About Santhera Pharmaceuticals Holding AG 
Santhera Pharmaceuticals Holding AG
Pharmaceuticals & Biotechnology
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Company Coordinates 
Company Details
Hohenrainstrasse 24 , PRATTELN None : 4133
Registrar Details






